JP2012197278A5 - - Google Patents

Download PDF

Info

Publication number
JP2012197278A5
JP2012197278A5 JP2012091882A JP2012091882A JP2012197278A5 JP 2012197278 A5 JP2012197278 A5 JP 2012197278A5 JP 2012091882 A JP2012091882 A JP 2012091882A JP 2012091882 A JP2012091882 A JP 2012091882A JP 2012197278 A5 JP2012197278 A5 JP 2012197278A5
Authority
JP
Japan
Prior art keywords
cdr
antigen
binding portion
tumor cells
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012091882A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012197278A (ja
JP5524270B2 (ja
Filing date
Publication date
Priority claimed from EP05011536A external-priority patent/EP1726650A1/en
Application filed filed Critical
Publication of JP2012197278A publication Critical patent/JP2012197278A/ja
Publication of JP2012197278A5 publication Critical patent/JP2012197278A5/ja
Application granted granted Critical
Publication of JP5524270B2 publication Critical patent/JP5524270B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2012091882A 2005-05-27 2012-04-13 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント Expired - Lifetime JP5524270B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05011536.9 2005-05-27
EP05011536A EP1726650A1 (en) 2005-05-27 2005-05-27 Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008512701A Division JP5038297B2 (ja) 2005-05-27 2006-03-02 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014017392A Division JP6110321B2 (ja) 2005-05-27 2014-01-31 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント

Publications (3)

Publication Number Publication Date
JP2012197278A JP2012197278A (ja) 2012-10-18
JP2012197278A5 true JP2012197278A5 (OSRAM) 2013-12-05
JP5524270B2 JP5524270B2 (ja) 2014-06-18

Family

ID=34937022

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2008512701A Expired - Lifetime JP5038297B2 (ja) 2005-05-27 2006-03-02 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント
JP2012091882A Expired - Lifetime JP5524270B2 (ja) 2005-05-27 2012-04-13 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント
JP2014017392A Expired - Lifetime JP6110321B2 (ja) 2005-05-27 2014-01-31 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント
JP2016063219A Pending JP2016190839A (ja) 2005-05-27 2016-03-28 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008512701A Expired - Lifetime JP5038297B2 (ja) 2005-05-27 2006-03-02 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014017392A Expired - Lifetime JP6110321B2 (ja) 2005-05-27 2014-01-31 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント
JP2016063219A Pending JP2016190839A (ja) 2005-05-27 2016-03-28 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント

Country Status (16)

Country Link
US (3) US8198416B2 (OSRAM)
EP (3) EP1726650A1 (OSRAM)
JP (4) JP5038297B2 (OSRAM)
CN (1) CN101233236B (OSRAM)
AT (1) ATE505544T1 (OSRAM)
AU (1) AU2006251445B2 (OSRAM)
CA (1) CA2609682C (OSRAM)
CY (1) CY1111409T1 (OSRAM)
DE (1) DE602006021296D1 (OSRAM)
DK (1) DK1883698T4 (OSRAM)
ES (1) ES2362795T5 (OSRAM)
PL (1) PL1883698T5 (OSRAM)
PT (1) PT1883698E (OSRAM)
RU (1) RU2458073C2 (OSRAM)
SI (1) SI1883698T2 (OSRAM)
WO (1) WO2006125481A1 (OSRAM)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105159B1 (en) 1992-11-05 2006-09-12 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
EP2360169B1 (en) 2001-10-23 2015-10-14 Psma Development Company, L.L.C. PSMA antibodies
EP1726650A1 (en) 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
GB0715542D0 (en) * 2007-08-09 2007-09-19 Imp Innovations Ltd Methods
SG186017A1 (en) 2007-11-30 2012-12-28 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
EP2281004A4 (en) * 2008-04-14 2012-02-15 Proscan Rx Pharma Inc PROSTATE-SPECIFIC MEMBRANANT ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
ITTO20080313A1 (it) * 2008-04-22 2009-10-23 Marco Colombatti Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi
DK2352763T4 (da) * 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
EP4180458A1 (en) * 2008-10-01 2023-05-17 Amgen Research (Munich) GmbH Cross-species-specific psma x cd3 bispecific single chain antibody
EP3495000A1 (en) * 2009-02-17 2019-06-12 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
TWI629357B (zh) * 2009-10-02 2018-07-11 安進研究（慕尼黑）有限責任公司 跨物種特異性的ＰＳＭＡｘＣＤ３雙特異性單鏈抗體
MX337600B (es) * 2009-12-02 2016-03-11 Imaginab Inc Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antigeno de membrana especifico para prostata de humano (psma) y metodos para su uso.
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
SG194510A1 (en) 2011-04-22 2013-12-30 Emergent Product Dev Seattle Prostate-specific membrane antigen binding proteins and related compositionsand methods
WO2013155605A1 (en) * 2012-04-19 2013-10-24 Innovascreen Inc. Method for predicting a pathophysiological condition in an animal
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
MX383614B (es) 2015-05-21 2025-03-14 Harpoon Therapeutics Inc Proteinas de union triespecificas y metodos de uso.
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
ES2987957T3 (es) 2015-11-23 2024-11-18 Novartis Ag Vectores de transferencia lentivirales optimizados y usos de los mismos
BR112018013074A2 (en) 2015-12-30 2018-12-11 Novartis Ag immune effector cell therapies with enhanced efficacy
CN105524171A (zh) * 2016-02-03 2016-04-27 中国人民解放军第三军医大学第三附属医院 一种针对前列腺特异性膜抗原的纳米抗体
CN105504061A (zh) * 2016-02-03 2016-04-20 南昌大学 针对前列腺特异性膜抗原的纳米抗体
CN105968201A (zh) * 2016-02-03 2016-09-28 南昌大学 针对前列腺特异性膜抗原的单域重链抗体
CN105542009A (zh) * 2016-02-03 2016-05-04 南昌大学 一种针对前列腺特异性膜抗原的单域重链抗体
CN105968202A (zh) * 2016-02-03 2016-09-28 南昌大学 针对前列腺特异性膜抗原胞外区的单域重链抗体
CN105968203A (zh) * 2016-02-03 2016-09-28 南昌大学 一种抗前列腺特异性膜抗原胞外区的单域重链抗体
CA3016287A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
EP3443096B1 (en) 2016-04-15 2023-03-01 Novartis AG Compositions and methods for selective expression of chimeric antigen receptors
AU2017267793B2 (en) 2016-05-20 2024-01-25 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
EP3490590A2 (en) 2016-08-01 2019-06-05 Novartis AG Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
US10844134B2 (en) 2016-11-23 2020-11-24 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
KR102275008B1 (ko) * 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
EP3574005B1 (en) 2017-01-26 2021-12-15 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
JP2020506700A (ja) 2017-01-31 2020-03-05 ノバルティス アーゲー 多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
US20200048359A1 (en) 2017-02-28 2020-02-13 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
SI3694529T1 (sl) 2017-10-13 2024-10-30 Harpoon Therapeutics, Inc. Trispecifične beljakovine in načini uporabe
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
KR20200086278A (ko) 2017-10-18 2020-07-16 노파르티스 아게 선택적 단백질 분해를 위한 조성물 및 방법
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
WO2019084288A1 (en) 2017-10-25 2019-05-02 Novartis Ag METHODS FOR DESIGNING CHIMERIC ANTIGENIC RECEPTOR EXPRESSION CELLS
WO2019089798A1 (en) 2017-10-31 2019-05-09 Novartis Ag Anti-car compositions and methods
JP2021505637A (ja) * 2017-12-12 2021-02-18 マクロジェニクス，インコーポレーテッド 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用
JP7857730B2 (ja) 2018-04-13 2026-05-13 ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング 固形腫瘍の治療のための標的化されたアマトキシン複合体
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
BR112020023330A2 (pt) 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. porção de ligação para ativação condicional de moléculas de imunoglobulina
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
US20210123075A1 (en) 2018-06-08 2021-04-29 Novartis Ag Compositions and methods for immunooncology
EP3587454A1 (en) 2018-06-27 2020-01-01 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors that bind to prostate specific membrane antigen
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
HRP20230115T1 (hr) * 2018-07-31 2023-06-09 Heidelberg Pharma Research Gmbh Humanizirana antitijela protiv psma
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
BR112021015672A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
ES3032659T3 (en) 2019-02-15 2025-07-23 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN110407939B (zh) * 2019-03-12 2023-09-29 广东医科大学附属第二医院 一种人源化抗psma单链抗体及其应用
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
KR20220008866A (ko) 2019-05-14 2022-01-21 하푼 테라퓨틱스, 인크. EpCAM 결합 단백질 및 사용 방법
KR20220116257A (ko) 2019-12-20 2022-08-22 노파르티스 아게 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
EP3842461A1 (en) * 2019-12-23 2021-06-30 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors that bind to prostate specific membrane antigen
WO2021164692A1 (zh) * 2020-02-18 2021-08-26 和铂医药(上海)有限责任公司 一种分离的结合抗原psma的蛋白及其用途
CN111303288B (zh) * 2020-03-04 2020-12-25 和铂医药(苏州)有限公司 一种分离的结合抗原psma的蛋白及其用途
CA3170833A1 (en) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
CN116096862A (zh) 2020-06-11 2023-05-09 诺华股份有限公司 Zbtb32抑制剂及其用途
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
IL299748A (en) 2020-07-08 2023-03-01 Lava Therapeutics N V Antibodies that bind PSMA and T gamma delta receptors
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
TW202309294A (zh) 2021-04-27 2023-03-01 瑞士商諾華公司 病毒載體生產系統
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
AU2023369684A1 (en) 2022-10-26 2025-04-17 Novartis Ag Lentiviral formulations
JP2026507228A (ja) 2023-03-03 2026-02-27 アーセナル バイオサイエンシズ インコーポレイテッド Ｐｓｍａ及びｃａ９を標的とするシステム
EP4720059A1 (en) 2023-05-24 2026-04-08 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2025235801A1 (en) 2024-05-08 2025-11-13 City Of Hope Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy
CN119735685B (zh) * 2025-03-04 2025-06-13 深圳真实生物医药科技有限公司 一种靶向前列腺特异性膜抗原的抗体、其抗原结合片段、制备方法及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162504A (en) * 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
AU6139794A (en) * 1993-02-10 1994-08-29 Unilever Plc Immobilized proteins with specific binding capacities and their use in processes and products
US6150508A (en) * 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
ATE318147T1 (de) * 1996-03-25 2006-03-15 Medarex Inc Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
ES2221703T3 (es) * 1997-02-26 2005-01-01 Sankyo Company Limited Compuesto azasteroide para el tratamiento o la prevencion del cancer de prostata.
US6258939B1 (en) * 1997-03-10 2001-07-10 The Regents Of The University Of California PSCA antibodies and hybridomas producing them
NZ517331A (en) * 1999-07-29 2004-02-27 Medarex Inc Human monoclonal antibodies to prostate specific membrane antigen and a transgenic mouse to produce the antibody
FR2797743B1 (fr) * 1999-08-23 2003-08-08 Urogene Lignee cellulaire prostatique et son utilisation pour l'obtention d'une tumeur prostatique etablie chez l'animal
JP4619651B2 (ja) * 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 前立腺特異的膜抗原に対する修飾抗体およびその使用
US20040242851A1 (en) * 2001-06-26 2004-12-02 Zhenping Zhu Bispecific antibodies that bind to vegf receptors
IL159422A0 (en) * 2001-09-20 2004-06-01 Cornell Res Foundation Inc Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
EP2360169B1 (en) * 2001-10-23 2015-10-14 Psma Development Company, L.L.C. PSMA antibodies
KR20040077889A (ko) * 2002-01-28 2004-09-07 메다렉스, 인코포레이티드 전립선 특이적 막 항원 (ｐｓｍａ)에 대한 인간모노클로날 항체
JP2004000045A (ja) * 2002-05-31 2004-01-08 Kyowa Hakko Kogyo Co Ltd 前立腺特異的膜抗原に対する抗体
US6641899B1 (en) * 2002-11-05 2003-11-04 International Business Machines Corporation Nonlithographic method to produce masks by selective reaction, articles produced, and composition for same
CA2514419A1 (en) * 2003-01-28 2004-08-12 Proscan Rx Pharma Inc. Prostate cancer diagnosis and treatment
JP2008526979A (ja) * 2005-01-14 2008-07-24 サイトジェン コーポレーション 抗ｐｓｍａ抗体による併用癌治療法
MX2007009878A (es) * 2005-02-18 2007-10-03 Medarex Inc Anticuerpos monoclonales para antigeno de membrana especifica para prostata (amep).
CN101160324B (zh) * 2005-02-18 2013-04-24 米德列斯公司 缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体
AU2006235421A1 (en) * 2005-04-08 2006-10-19 Cytogen Corporation Conjugated anti-PSMA antibodies
EP1726650A1 (en) * 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
CN103127523A (zh) * 2005-06-20 2013-06-05 Psma开发有限公司 Psma抗体-药物缀合物

Similar Documents

Publication Publication Date Title
PH12021551720A1 (en) Dll3 targeting chimeric antigen receptors and binding agents
CN113316591A (zh) Cd73抗体及其制备方法和应用
HK1210620A1 (en) Multi-specific monoclonal antibodies
WO2014012085A3 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
MX2022015823A (es) Receptores de antigenos quimerlcos basados en anticuerpos de dominio simple y metodos de uso de estos.
HK1207398A1 (en) Cd3 binding polypeptides
HK1199837A1 (en) Humanized antibodies to inkt
WO2012088247A3 (en) Anti-c5/c5a/c5adesr antibodies and fragments
RU2017132160A (ru) Антитела к pd-l1 и их применение для усиления функции t-клеток
AU2018253589A1 (en) Antibodies, pharmaceutical compositions and uses thereof
EA201491524A1 (ru) Связывающиеся с эритроцитами терапевтические средства
MX359384B (es) Conjunto mejorado de anticuerpos bisespecificos.
WO2015092024A3 (en) Method of engineering multi-input signal sensitive t cell for immunotherapy
WO2015054691A3 (en) Tem8 antibodies and their use
EA201790175A1 (ru) Применение модифицированных t-клеток с химерными антигенными рецепторами для лечения злокачественных новообразований
CR20110577A (es) Proteínas de unión a il-1
WO2015069922A3 (en) Alk antibodies, conjugates, and chimeric antigen receptors, and their use
WO2014011993A3 (en) Epitope spreading associated with car t-cells
CL2014000574A1 (es) Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano.
NZ623086A (en) Therapeutic peptides
WO2012047732A3 (en) Antibody compositions and methods of use
EP4253959A3 (en) Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
EA201500502A1 (ru) Связывающие антиген her3 белки, связывающиеся с бета-шпилькой her3
WO2011108008A3 (en) Antibody for targeted induction of apoptosis, cdc and adcc mediated killing of cancer cells, tbl-cln1